Four cases of cardiopulmonary thromboembolism during liver transplantation without the use of antifibrinolytic drugs

Anesthesia and Analgesia

Volumn 101, Issue 6, 2005, Pages 1608-1612

  Lerner, Adam B ^a,b   Sundar, Eswar ^a   Mahmood, Feroze ^a   Sarge, Todd ^a   Hanto, Douglas W ^a   Panzica, Peter J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BIDMC Department of OB GYN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; HEPARIN;

ADULT; BLEEDING; CASE REPORT; FEMALE; HUMAN; INTRACARDIAC THROMBOSIS; LIVER TRANSPLANTATION; LUNG EMBOLISM; MALE; MORBIDITY; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SURGICAL MORTALITY; THROMBOELASTOGRAPHY; TREATMENT INDICATION;

EID: 28344438553     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000184256.28981.2B     Document Type: Article

References (40)

1. Navalgund AA, Kang Y, Sarner JB, et al. Massive pulmonary thromboembolism during liver transplantation. Anesth Analg 1988;67:400-2.
2. O'Connor CJ, Roozeboom D, Brown R, Tuman KJ. Pulmonary thromboembolism during liver transplantation: possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg 2000;91:296-9.
3. Prah GN, Lisman SR, Maslow AD, et al. Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation: two case reports. Transplantation 1995;59:921-5.
4. Sopher M, Braunfeld M, Shackleton C, et al. Fatal pulmonary embolism during liver transplantation. Anesthesiology 1997;87:429-32.
5. Wong WH, Braunfeld M, Levin P. Recurrent pulmonary embolism during liver transplantation: possible role of hepatitis B immune globulin as a causative agent. Anesthesiology 2002;96:1261-3.
6. Baubillier E, Cherqui D, Dominique C, et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 1994;57:1664-6.
7. Ellis JE, Lichtor JL, Feinstein SB, et al. Right heart dysfunction, pulmonary embolism, and paradoxical embolization during liver transplantation. A transesophageal two-dimensional echocardiographic study. Anesth Analg 1989;68:777-82.
8. Fitzsimons MG, Peterfreund RA, Raines DE. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 2001;92:1418-21.
9. Gologorsky E, De Wolf AM, Scott V, et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2001;7:783-9.
10. Manji M, Isaac JL, Bion J. Survival from massive intraoperative pulmonary thromboembolism during orthotopic liver transplantation. Br J Anaesth 1998;80:685-7.
11. Planinsic RM, Nicolau-Raducu R, Eghtesad B, Marcos A. Diagnosis and treatment of intracardiac thrombosis during orthotopic liver transplantation. Anesth Analg 2004;99:353-6.
12. Ramsay MA, Randall HB, Burton EC. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transpl 2004;10:310-4.
13. Merion RM. When is a patient too well and when is a patient too sick for a liver transplant? Liver Transpl 2004;10:S69-73.
14. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
15. Lerut J, Gertsch P, Blumgart LH. "Piggy back" adult orthotopic liver transplantation. Helv Chir Acta 1989;56:527-30.
16. Carmassi F, Morale M, De Negri F, Carrai M. Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis. J Mol Med 1995;73:89-93.
17. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992;6:1247-57.
18. Bakker CM, Metselaar HJ, Gomes MJ, et al. Intravascular coagulation in liver transplantation: is it present or not?-A comparison between orthotopic and heterotopic liver transplantation. Thromb Haemost 1993;69:25-8.
19. Harper PL, Luddington RJ, Jennings I, et al. Coagulation changes following hepatic revascularization during liver transplantation. Transplantation 1989;48:603-7.
20. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989;47:978-84.
21. Porte RJ. Antifibrinolytics in liver transplantation: they are effective, but what about the risk-benefit ratio? Liver Transpl 2004;10:285-8.
22. Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl 2005;11:10-8.
23. Dalmau A, Sabate A, Koo M, et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl 2004;10:279-84.
24. Findlay JY, Rettke SR, Ereth MH, et al. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl 2001;7:802-7.
25. Garcia-Huete L, Domenech P, Sabate A, et al. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: a randomized clinical study. Hepatology 1997;26:1143-8.
26. Grosse H, Lobbes W, Frambach M, et al. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. Thromb Res 1991;63:287-97.
27. Kang Y. Clinical use of synthetic antifibrinolytic agents during liver transplantation. Semin Thromb Hemost 1993;19:258-61.
28. Molenaar IQ, Legnani C, Groenland TH, et al. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 2001;7:896-903.
29. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study: EMSALT Study Group. Lancet 2000;355:1303-9.
30. Porte RJ, Slooff MJ. Aprotinin: safe and effective in all patients undergoing orthotopic liver transplantation? Liver Transpl 2001;7:808-10.
31. Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 1995;21:34-44.
32. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-8.
33. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
34. De Wolf AM, Ramsay G, Teruya J, et al. Hypercoagulability and pulmonary thromboembolism during OLT: what is the role of heparin administration. Liver Transpl Surg 2001;7:C-5.
35. Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997;26:554-9.
36. Abrahams JM, Torchia MB, McGarvey M, et al. Perioperative assessment of coagulability in neurosurgical patients using thromboelastography. Surg Neurol 2002;58:5-11.
37. Cerutti E, Stratta C, Romagnoli R, et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl 2004;10. 289-94.
38. Pivalizza EG, Pivalizza PJ, Weavind LM. Perioperative thromboelastography and sonoclot analysis in morbidly obese patients. Can J Anaesth 1997;44:942-5.
39. Sharma SK, Philip J, Wiley J. Thromboelastographic changes in healthy parturients and posrpartum women. Anesth Analg 1997;85:94-8.
40. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005;100:1576-83.